וויגובי 0.5 מ"ג - Wegovy 0.5 mg

AdultsWegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

• ≥30 kg/m2 (obesity), or
• ≥27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.For trial results with respect to cardiovascular risk reduction and populations studied, see section 5.1.Adolescents (≥12 years)Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with
• obesity* and
• body weight above 60 kg.Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.*Obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth charts.